Key Highlights

  • Post-earnings selling pressure continues following the company's Q2 miss last week, where EPS of -$0.81 came in below the -$0.72 consensus and revenue of $9.04 million badly missed the $15.29 million estimate.
  • Despite the earnings disappointment, a wave of analyst price target upgrades — Stifel to $40, Mizuho to $34, RBC to $33, and Truist to $34 — reflect bullish conviction in the company's Roche collaboration for bexobrutideg.
  • That collaboration carries up to $2.3 billion in potential payments, including a $700 million upfront payment, underpinning the long-term bull case even amid today's decline.

Nurix Therapeutics (NASDAQ: NRIX) shares are tumbling 6% today, underperforming the broader healthcare sector, as investors weigh a mix of company-specific catalysts and broader macro developments.

Post-earnings selling pressure continues following the company's Q2 miss last week, where EPS of -$0.81 came in below the -$0.72 consensus and revenue of $9.04 million badly missed the $15.29 million estimate. Despite the earnings disappointment, a wave of analyst price target upgrades — Stifel to $40, Mizuho to $34, RBC to $33, and Truist to $34 — reflect bullish conviction in the company's Roche collaboration for bexobrutideg.

That collaboration carries up to $2.3 billion in potential payments, including a $700 million upfront payment, underpinning the long-term bull case even amid today's decline.

Today's move is also unfolding against a broader risk backdrop, as renewed U.S.-Iran hostilities have sent oil prices sharply higher and injected a risk-off tone across equity markets. The healthcare sector, tracked by the XLV ETF, is itself navigating this volatile macro environment, with investors weighing geopolitical headline risk alongside company-specific fundamentals heading into a pivotal earnings season.

Looking ahead, investors will be watching how Nurix Therapeutics's next earnings report and any further analyst commentary shape the stock's trajectory, particularly as markets continue to digest both company-specific catalysts and the broader macro backdrop of geopolitical tension and shifting interest rate expectations.